A CREB1-miR-181a-5p loop regulates the pathophysiologic features of bone marrow stromal cells in fibrous dysplasia of bone.
Apoptosis
Biomarkers
Cell Differentiation
/ genetics
Cell Proliferation
Cells, Cultured
Cyclic AMP Response Element-Binding Protein
/ metabolism
Disease Susceptibility
Fibrous Dysplasia of Bone
/ etiology
Gene Expression Regulation
Humans
Mesenchymal Stem Cells
/ metabolism
MicroRNAs
/ genetics
Models, Biological
Osteoclasts
/ cytology
Osteogenesis
/ genetics
Apoptosis
Bone marrow stromal cells
CREB
Fibrous dysplasia
Proliferation
miR-181a-5p
Journal
Molecular medicine (Cambridge, Mass.)
ISSN: 1528-3658
Titre abrégé: Mol Med
Pays: England
ID NLM: 9501023
Informations de publication
Date de publication:
22 07 2021
22 07 2021
Historique:
received:
21
01
2021
accepted:
06
07
2021
entrez:
23
7
2021
pubmed:
24
7
2021
medline:
14
1
2022
Statut:
epublish
Résumé
Fibrous dysplasia (FD) is a bone marrow stromal cell (BMSC) disease caused by activating mutations of guanine nucleotide-binding protein alpha-stimulating activity polypeptide (GNAS) and is characterized by increased proliferative activity and disrupted osteogenesis of BMSCs. However, the molecular mechanisms regulating the pathophysiologic features of BMSCs in FD remain unknown. This study aimed to identify and verify the roles of the CREB1-miR-181a-5p regulatory loop in FD pathophysiology. MicroRNA (miRNA) sequencing analysis was used to identify the possible miRNAs implicated in FD. The proliferation, apoptosis, and osteogenic differentiation of BMSCs, as well as the osteoclast-induced phenotype, were measured and compared after exogenous miR-181a-5p transfection into FD BMSCs or miR-181a-5p inhibitor transfection into normal BMSCs. Chromatin immunoprecipitation and luciferase reporter assays were performed to verify the interactions between CREB1 and miR-181a-5p and their effects on the FD pathological phenotype. Compared to normal BMSCs, FD BMSCs showed decreased miR-181a-5p levels and exhibited increased proliferative activity, decreased apoptotic capacity, and impaired osteogenesis. FD BMSCs also showed a stronger osteoclast activation effect. miR-181a-5p overexpression reversed the pathophysiologic features of FD BMSCs, whereas miR-181a-5p suppression induced an FD-like phenotype in normal BMSCs. Mechanistically, miR-181a-5p was the downstream target of CREB1, and CREB1 was posttranscriptionally regulated by miR-181a-5p. Our study identifies that the interaction loop between CREB1 and miR-181a-5p plays a crucial role in regulating the pathophysiologic features of FD BMSCs. MiR-181a-5p may be a potential therapeutic target for the treatment of FD.
Sections du résumé
BACKGROUND
Fibrous dysplasia (FD) is a bone marrow stromal cell (BMSC) disease caused by activating mutations of guanine nucleotide-binding protein alpha-stimulating activity polypeptide (GNAS) and is characterized by increased proliferative activity and disrupted osteogenesis of BMSCs. However, the molecular mechanisms regulating the pathophysiologic features of BMSCs in FD remain unknown. This study aimed to identify and verify the roles of the CREB1-miR-181a-5p regulatory loop in FD pathophysiology.
METHODS
MicroRNA (miRNA) sequencing analysis was used to identify the possible miRNAs implicated in FD. The proliferation, apoptosis, and osteogenic differentiation of BMSCs, as well as the osteoclast-induced phenotype, were measured and compared after exogenous miR-181a-5p transfection into FD BMSCs or miR-181a-5p inhibitor transfection into normal BMSCs. Chromatin immunoprecipitation and luciferase reporter assays were performed to verify the interactions between CREB1 and miR-181a-5p and their effects on the FD pathological phenotype.
RESULTS
Compared to normal BMSCs, FD BMSCs showed decreased miR-181a-5p levels and exhibited increased proliferative activity, decreased apoptotic capacity, and impaired osteogenesis. FD BMSCs also showed a stronger osteoclast activation effect. miR-181a-5p overexpression reversed the pathophysiologic features of FD BMSCs, whereas miR-181a-5p suppression induced an FD-like phenotype in normal BMSCs. Mechanistically, miR-181a-5p was the downstream target of CREB1, and CREB1 was posttranscriptionally regulated by miR-181a-5p.
CONCLUSIONS
Our study identifies that the interaction loop between CREB1 and miR-181a-5p plays a crucial role in regulating the pathophysiologic features of FD BMSCs. MiR-181a-5p may be a potential therapeutic target for the treatment of FD.
Identifiants
pubmed: 34294046
doi: 10.1186/s10020-021-00341-z
pii: 10.1186/s10020-021-00341-z
pmc: PMC8296714
doi:
Substances chimiques
Biomarkers
0
CREB1 protein, human
0
Cyclic AMP Response Element-Binding Protein
0
MIRN-181 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
81Informations de copyright
© 2021. The Author(s).
Références
J Bone Miner Res. 2020 Oct;35(10):1881-1892
pubmed: 32526052
Hum Mol Genet. 2007 Aug 15;16(16):1921-30
pubmed: 17566083
J Mol Endocrinol. 2010 Dec;45(6):355-64
pubmed: 20841428
Head Face Med. 2009 Nov 09;5:22
pubmed: 19895712
Exp Gerontol. 2014 Aug;56:154-63
pubmed: 24607549
J Pathol. 2012 Sep;228(1):45-55
pubmed: 22450860
Mol Cancer. 2009 Oct 30;8:93
pubmed: 19878573
Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E418-E427
pubmed: 29158412
Mol Aspects Med. 2019 Dec;70:90-105
pubmed: 31703947
Cell Prolif. 2020 Oct;53(10):e12900
pubmed: 32914514
Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E428-E437
pubmed: 29282319
Horm Metab Res. 2012 Sep;44(10):724-31
pubmed: 22903279
Exp Gerontol. 2016 Nov;84:71-79
pubmed: 27599698
J Bone Miner Res. 2019 Feb;34(2):290-294
pubmed: 30496606
Int J Biochem Cell Biol. 2013 Mar;45(3):696-705
pubmed: 23262291
Nat Rev Mol Cell Biol. 2019 Jan;20(1):5-20
pubmed: 30228348
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2209-18
pubmed: 24966929
Cells. 2019 Feb 03;8(2):
pubmed: 30717449
Stem Cells Transl Med. 2019 Feb;8(2):148-161
pubmed: 30426726
BMC Vet Res. 2018 May 2;14(1):152
pubmed: 29720166
Nat Rev Mol Cell Biol. 2001 Aug;2(8):599-609
pubmed: 11483993
J Neurochem. 2013 Sep;126(6):771-80
pubmed: 23865718
Curr Opin Immunol. 2007 Oct;19(5):488-96
pubmed: 17629468
J Physiol Biochem. 2011 Mar;67(1):129-39
pubmed: 20981514
Chin Med J (Engl). 2012 Feb;125(3):523-6
pubmed: 22490414
Science. 1997 Dec 12;278(5345):1966-8
pubmed: 9395403
J Exp Clin Cancer Res. 2019 Jul 17;38(1):315
pubmed: 31315644
Curr Opin Genet Dev. 2005 Oct;15(5):563-8
pubmed: 16099643
FASEB J. 2019 Apr;33(4):5208-5219
pubmed: 30624969
BMC Musculoskelet Disord. 2016 Feb 16;17:83
pubmed: 26879131
Mitochondrion. 2012 Mar;12(2):213-9
pubmed: 21958558
Expert Rev Mol Med. 2012 Feb 21;14:e5
pubmed: 22348355
J Dent Res. 2014 Sep;93(9):904-10
pubmed: 24972872
Cancer Lett. 2012 Jan 28;314(2):155-65
pubmed: 22014978
Nat Rev Mol Cell Biol. 2019 Jan;20(1):21-37
pubmed: 30108335
Cancer Metastasis Rev. 2018 Mar;37(1):17-32
pubmed: 29327093
Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Sep;116(3):e149-55
pubmed: 23953425
Cell Death Dis. 2014 Apr 10;5:e1161
pubmed: 24722286
J Dent Res. 2017 May;96(5):491-500
pubmed: 28068481
Endocr Rev. 2020 Apr 1;41(2):
pubmed: 31673695
Nat Rev Mol Cell Biol. 2014 Aug;15(8):509-24
pubmed: 25027649
FASEB J. 2015 Sep;29(9):3935-44
pubmed: 26062603
Pediatr Endocrinol Rev. 2007 Aug;4 Suppl 4:386-94
pubmed: 17982385
Cells. 2019 Nov 19;8(11):
pubmed: 31752361
Nat Chem Biol. 2019 Apr;15(4):322-330
pubmed: 30718816
Brief Bioinform. 2015 Jan;16(1):45-58
pubmed: 24307685
Oncol Rep. 2010 Apr;23(4):997-1003
pubmed: 20204284
Cell Signal. 2008 Mar;20(3):460-6
pubmed: 17993258
J Cell Mol Med. 2019 Jan;23(1):522-534
pubmed: 30451360
Tumour Biol. 2016 Jul;37(7):8487-502
pubmed: 27059735
J Bone Miner Res. 2019 Apr;34(4):653-660
pubmed: 30645769